Hi everyone, although I have had P for several year, this is the first time I began searching for support forums like this one and I am glad I did.   My P has been pretty bad for a long time now and I have been trying to stay away from biologics but decided to try them about 5 months ago. My Dr put me on Humira and after 4 months, not only did I not improve, I got much worse. Yesterday Morning I took my first shots of Taltz. You may think I'm crazy or am seeing thing due to my desire to get clear, but I swear I can already see a change in the way my patches look. Anyways, I hope to make some new friends here and be helped by, and help others.

First post here...
Bee a sufferer of psoriasis for 40+years and are currently having a breakout after coming off fumaderm about 20 months ago.

I'm a bit annoyed with the NHS if im honest. I went to the doctors to get referred to the hospital, to cut a long story short, I booked online to a different hospital as they could see me far quicker than my usual hospital we are talking weeks earlier here. Anyway when I go to this hospital to see about getting fumaderm again, they tell me they cannot prescribe that at this hospital. They then discharge me and I'm now waiting for another referral to the local Hospital.

Not sure why they gave me the option of the other hospital when they can't prescribe what I need.

Recently I have been on betnovate scalp application, this isn't working, it dries the psoriasis up but it doesn't clear it. I've. Been on dovonex, dovobet and are currently.on exorex.

Hello I am 22 years old. I've had guttate psoriasis for 4/5 years. Looking for success stories and starting tommorow I will be starting a diary where I keep track of new things I'm trying in order to get rid of the p!

This is an abstract of a study that looked at the use of light treatment in patients with nail psoriasis.

Quote:

---

Abstract:

Psoriatic involvement of the nail is notoriously refractory to conventional therapy. Nail psoriasis has a high incidence amongst patients with psoriasis. It remains a significant cosmetic problem and thus, has a significant impact on quality of life.

More recently, light and laser therapies have emerged as modalities for treatment of nail psoriasis. In this study, the efficacies of light and laser therapies are systematically reviewed.

Light therapies involve ultraviolet light (with or without photosensitizers) or intense pulsed light. Alternatively, laser therapy in nail psoriasis is primarily administered using a 595-nm pulsed dye laser. These modalities have demonstrated significant improvement in psoriatic nail lesions, and even complete resolution in some cases. Both laser and light modalities have also been tested in combination with other systemic or topical therapeutics, with variable improvement in efficacy. Both laser and light therapies are generally well tolerated.

Side-effects of light therapies include hyperpigmentation, itching and erythema; whereas, side-effects of laser therapy are more frequent and include pain, purpura/petechiae and hyperpigmentation. Patterns of response to therapy were also seen based on presenting characteristics of the nail lesions: subungual hyperkeratosis and onycholysis appeared to be the most responsive to therapy, while nail pitting was the most resistant.

Light or laser therapies have the potential to be an efficient and cost-effective in-office based treatment for nail psoriasis. However, more large-scale clinical trials are needed to assess their efficacy, particularly in combination with other therapeutic modalities.

This study looked at the prevalence of biological liver test abnormalities in psoriasis patients during psoriasis flares.

Quote:

---

Background:
Few epidemiologic data are available regarding biologic liver abnormalities during psoriasis flares.

Objectives:
The aim of this study was to assess the prevalence of biological liver test abnormalities (LTA) in a psoriasis population and the risk factors associated with LTA.

Methods:
A retrospective cross-sectional study in four hospital dermatology tertiary care centres included patients admitted for severe psoriasis flare between 1st January 2010 and 31st December 2011. During the same period, a control population was selected comprising patients admitted for contact and/or atopic eczema. Data were collected on hospital records and biology software. LTA was defined as serum AST and/or ALT and/or ALP concentration above the upper normal limit (UNL) and/or GGT concentration above 2 UNL. Prevalence of LTA with 95% confidence intervals (95% CI) was compared between the psoriatic and control populations. Factors associated with LTA at P < 0.05 were considered for the final multivariate logistic regression model.

Results:
Two hundred and forty psoriasis patients and 96 eczema control patients were included. One hundred and fifty-five(64.6%) of the psoriasis patients were male, aged 55 years on average (±17.6); 192 (80.0%) had plaque-type psoriasis (PV) and 52 (21.6%) had localized (n = 32) or generalized (n = 20) pustular psoriasis (PP). Prevalence of LTA was 36% (95% CI, 30–42) in the psoriatic population, significantly higher than in controls (17%, 95% CI 9.5–25). Risk factors independently associated with LTA comprised PV (OR 3.79; 95% CI 1.48–9.65), PP (OR 3.80; 95% CI 1.40–10.25) and previously diagnosed liver disease (underlying hepatic steatosis, viral hepatitis or excessive alcohol consumption) (OR 3.88; 95% CI 2.02–7.45). No association was found with systemic antipsoriatic drug therapies.

Conclusion:
In severe psoriasis, liver impacting comorbidities and/or specific psoriatic inflammation, the latter mostly in PP cases, more than drug-related liver toxicity, appears to predominantly account for LTA. Clinicians should be aware of this, to avoid unjustified withdrawal of useful systemic drugs.

Hello! I'm Loreta from Philippines and I'm newly diagnosed with psoriasis last March 26, a month after my 16th birthday. See, I'm very active in school and hearing my doctor say that I should "avoid stress" is probably my killer. I love school and all activities. Yet, it's the cause of my problems. 

On another note, I'm new to this illness and I'm getting tired of it. It hurts sometimes and my scalp itches like hell and my nails are starting to be detached from my fingers. It's hard for me to process these things considering that I'm very young and this was very unexpected as we were only eyeing for eczema. 

But, don't get me wrong. Life is still beautiful!!!

Hi everyone,  my name is John Im 68 and Ive just had a bad flare of (P) which has taken me by surprise.  I have in the past maybe once a year had the odd elbow flare but did not know this was (P) so just ignored it and it usually just went away a week or so later. However I have had a very bad problem (which Ive had for a long time)  like two years or so on the sole of my left foot and I kept scratching it so needless to say it just got worse and worse developing into a large red shiny patch until eventually I went to the Doctor last week. I showed him the foot and also the elbows.  He gave me antibiotic cream for the foot which is to be followed by Betnovate Cream for two weeks.  The latter is to be used on the foot and the Elbows.  

It has in the last few days spread to both hands and has made my palms very uncomfortable and itchy with the red patches and lots of small raised blister like bumps, certainly not the best thing to happen to a Guitar player.  It would appear from a number of comments ive read that the intense scratching of the sole of my foot  may well have caused this problem.  I do have a glass of wine each day with my dinner which ive done for years without any problem so I repeat its more likely to be the result of Scratching the foot. It has also affected the scalp at the back of my head.  So its obviously distressing to me as Ive only ever had the odd Elbow irritation.  It looks like I may be making some progress with clearing up the sole of the foot following the antibiotic cream use and im not scratching it now.

I would appreciate if anyone can offer me some ideas that would help with my palms as the other areas I can put up with.  As this outbreak is new to me, is there any chance that this will be a short episode and  dissapear again?  or am I going to be stuck with these difficult palms from here on in. its only 6 days yet but so far the Betnovate hasnt helped.  Has anyone found a product that clears it up for them?  

Sorry to be so long winded.

John

I read Freds post on salt and it made me curious if others have a salt trigger for P.
I have known for years that my plaque P. always was seasonal , foods never seemed to be a trigger for me. It's what I put on them that I now realize is one of my triggers. SALT. I have always added salt to all my foods.

Research in mice shows a high-salt diet can speed the progression of autoimmune diseases. Some may find reducing salt in their diets can help their psoriasis. I have replaced salt with spices and eat no prepared foodsfor the past 3 months.

Below is a quote from a study from a scientific study from UCLA.
"Could something as simple as a high-salt diet cause your psoriasis to progress more quickly? It’s too soon to say for sure, but research published in the journal UCLA Science research Center found that when mice are fed high-salt diets, they overproduce immune-system cells that attack their own tissues."

As we all know autoimmune disease is one where your body mistakes its own cells for foreign invaders and attacks them. Psoriasis is an autoimmune disorder in which something triggers your immune system to mistake normal skin cells as foreigners. You then overproduce new skin cells that cause raised, red, flaky lesions to form as well as PSA.

Quote."The high-salt diet the mice were fed stimulated a type of white blood cells — T-cells called Th17 cells.“It has been clearly shown that Th17 cells trigger psoriasis,” Dr. Yamauchi said." That’s why some of the drugs that have been developed to treat psoriasis, such as the biologic Stelara (ustekinumab), target the pathways driven by Th17 cells. Yamauchi noted that new biologics are in the pipeline for psoriasis that also target the Th17 pathway."

I thought this was interesting for all the PC members taking Stelera if anyone had noticed that eating salt was a trigger. I know now it's one of my triggers. Just as a example of my salt intake it's horrendous. Not good at all for many other reasons. This could be why my P. seems to be worse from drinking Margaritas, salty nuts, pop corn etc., with all that extra salt in prepared foods. Now it makes sence. i have cut down my total salt intake, substitute spices the past 3 months & noticed my P. / itching has calmed down with less spots and itching.

Anyone else noticed what their triggers for P. are and has it helped your Psoriasis to cut out your triggers?
Food, stress, winters, drug reactions,  insect bites, scratches cleaning chemicals?

Hey guys,

I've been fumaderm for almost a year and a half now, and anyone who has read my member journals knows that I had pretty good success with it. I was on 6x120 mg a day. Within a few months, I was virtually clear. I was told to cut down to 5x120mg, due to concerns over my protein levels. The psoriasis patches started to come back, but I wasn't overly concerned at first since it was very minor. Then, after a couple months, I was told to increase my dosage again.

5 months later, and I've noticed that the psoriasis patches are increasing even more. I went from patches on the chest area and lower back, to my stomach, sides and arms. Even my scalp psoriasis has come back. I assumed that by going back up in my dosage that it would improve, not slowly start to come back.

Has this happened to anyone else on fumaderm? I'm starting to worry that the medication is no longer working as it should for me, but I'm hoping that I'm worrying over nothing.

I am writing again on behalf of my husband who is 77. He was taken off the Ciclosporin and the Fumaderm because although it helped his psoriasis very much, it apparently caused liver kidney problems. He had been tried on various creams for a period of two years and also Acitretin before these more potent drugs were offered.
His kidney function went down to 9% and he was in hospital for a week - he is now out and his kidney function is slowly rising. Not sure of cause of drop from 50-9% over two weeks - could be painkillers, antibiotics psoriasis drugs.

To cut a long story short he is on the very lowest dose of ACitretin of 25g a day. Last year the dermatologist said that if the Fumaderm did not work he would have to go for the Bio injections. Well he has been for initial assessment and the man said his condition was not bad enough for it to be considered. His skin is peeling off in sheets of his feet, risk of infection a nightmare especially as antibiotics could cause kidney problems and neither of us have any quality of life as he is struggling to walk.

I know Bio's are a last resort and I know they cost the NHS a lot of money. I did contact Eric's dermatologist by phone just to make sure I understood correctly that he had wanted to progress the Bio option, and he said he did given the circumstances and the fact we had tried the other options. He did say he would write urgently to the Head of the Bio Unit and put our case forward. This was  2 weeks ago. The Nephrologist has said she will contact the Dermo so we can try and get some kind of treatment plan as I understand that Bio's can take a while to kick in.

I just wonder if anyone had to fight to this degree? I do know Eric is difficult with his co-morbidities and also his Lupus but  we are literally looking at having to buy a wheelchair soon or he will be totally housebound. 

Any comments gratefully received.  WE cannot afford to go privately with the Bio injections and forgive me, we have both been high rate tax payers for most of our lives. Is this just NHS lack of communication between Departments?             Helena

This study looked at the relationship between psoriasis and hepatitis C.

Quote:

---

Background:
Multiple studies have noted an association between hepatitis C and psoriasis, but it is not known whether psoriasis is a result of treatment modalities for hepatitis C or a result of hepatitis C alone.

Objective:
To examine the relationship between psoriasis and hepatitis C by measuring the expression of cathelicidin, TLR9 and IFNγ in psoriatic lesional and non-lesional skin in HCV-positive and negative psoriatic patients.

Methods:
Two 2 mm punch biopsies of lesional and non-lesional skin in 10 patients who were HCV-negative psoriatics and seven HCV-positive psoriatics were used to measure cathelicidin, TLR9 and IFNγ mRNA expression by quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR).

Results:
The mRNA levels of cathelicidin, TLR9 and IFNγ were significantly higher in both non-lesional and lesional skin of HCV-positive patients with psoriasis as compared to HCV-negative psoriatic patients. Additionally, the IFNγ level in lesional skin of HCV-positive psoriatic patients was higher than the IFNγ level seen in non-lesional skin of those same patients.

Conclusion:
These findings suggest that HCV infection upregulates these inflammatory cytokines, possibly increasing susceptibility to developing psoriasis.

For those of you thinking about using a telemedicine website or app to diagnose psoriasis you may want to think again.

Quote:

---

Abstract:

Importance:  
Evidence supports use of teleconsultation for improving patient access to dermatology. However, little is known about the quality of rapidly expanding direct-to-consumer (DTC) telemedicine websites and smartphone apps diagnosing and treating skin disease.

Objective:  
To assess the performance of DTC teledermatology services.

Design and Participants:  
Simulated patients submitted a series of structured dermatologic cases with photographs, including neoplastic, inflammatory, and infectious conditions, using regional and national DTC telemedicine websites and smartphone apps offering services to California residents.

Main Outcomes and Measures:  
Choice of clinician, transparency of credentials, clinician location, demographic and medical data requested, diagnoses given, treatments recommended or prescribed, adverse effects discussed, care coordination.

Results:  
We received responses for 62 clinical encounters from 16 DTC telemedicine websites from February 4 to March 11, 2016. None asked for identification or raised concerns about pseudonym use or falsified photographs. During most encounters (42 [68%]), patients were assigned a clinician without any choice. Only 16 (26%) disclosed information about clinician licensure, and some used internationally based physicians without California licenses. Few collected the name of an existing primary care physician (14 [23%]) or offered to send records (6 [10%]). A diagnosis or likely diagnosis was proffered in 48 encounters (77%). Prescription medications were ordered in 31 of 48 diagnosed cases (65%), and relevant adverse effects or pregnancy risks were disclosed in a minority (10 of 31 [32%] and 6 of 14 [43%], respectively). Websites made several correct diagnoses in clinical scenarios where photographs alone were adequate, but when basic additional history elements (eg, fever, hypertrichosis, oligomenorrhea) were important, they regularly failed to ask simple relevant questions and diagnostic performance was poor. Major diagnoses were repeatedly missed, including secondary syphilis, eczema herpeticum, gram-negative folliculitis, and polycystic ovarian syndrome. Regardless of the diagnoses given, treatments prescribed were sometimes at odds with existing guidelines.

Conclusions and Relevance:  
Telemedicine has potential to expand access to high-value health care. Our findings, however, raise concerns about the quality of skin disease diagnosis and treatment provided by many DTC telemedicine websites. Ongoing expansion of health plan coverage of these services may be premature. Until improvements are made, patients risk using health care services that lack transparency, choice, thoroughness, diagnostic and therapeutic quality, and care coordination. We offer several suggestions to improve the quality of DTC telemedicine websites and apps and avoid further growth of fragmented, low-quality care.

Quote:In the case of secondary syphilis with unusual plaques, the patient was not asked about his recent fever (even when he proactively reported it on ROS), and no clinician seemed concerned that his diffuse eruption began so acutely only 3 weeks previously without a history of prior skin eruptions (uncommon in patients with large-plaque psoriasis). Seven of the 8 clinicians diagnosed psoriasis, including 1 who did not ask for photographs. One clinician (an emergency physician) made no diagnosis and referred the patient to see a local dermatologist, and another (a Sweden-based physician) who diagnosed psoriasis suggested that the patient see a local dermatologist for treatment. This patient received prescriptions for class I or II topical steroids in 5 encounters and was told to use moisturizers and take lukewarm baths in another.

The young man with highly infectious secondary syphilis was not asked about his recent fevers, attention was not paid to the unusually sudden onset he described, and all but 1 of the websites accepted the diagnosis of psoriasis the patient himself offered. This not only left him at substantial risk from untreated syphilis, but was a public health failure given the urgent need for contact tracing and risks of ongoing transmission.

My friends psoriasis has been pretty persistently affecting hi sfingernails and toenails.
Would like to get that fied and or find somebody who knows more lot about it.
thank you.

HI EVERYONE!

This study looked at the working of antipsoriatic effect of calcipotriol.

Quote:

---

Background:
Calcipotriol ameliorates psoriasis through inducing keratinocyte apoptosis and inhibiting nuclear factor kappa B (NF-κB) activation, while zinc finger protein A20 exhibits an anti-apoptotic effect on various types of cells.

Objectives:
To understand the potential role of A20 in calcipotriol function.

Materials and methods:
The A20 levels were evaluated in the psoriatic skins from both human patients and K14-vascular endothelial growth factor (VEGF) transgenic mice that received or did not receive topical calcipotriol treatment. The in vitro effect of calcipotriol on A20 expression and the downstream NF-κB pathway was studied using a model of human foreskin keratinocytes (HFKs) that were stimulated with psoriatic cytokines [M5, a cocktail of interleukin (IL)-1a, IL-17A, IL-22, Oncostatin M and tumour necrosis factor-α, each at 10 ng mL−1].

Results:
A20 expression was enhanced in both psoriatic tissues and keratinocytes when compared with controls, but decreased on calcipotriol treatment. The transfection of A20 small interfering RNA (siRNA) improved cell differentiation, and inhibited psoriatic inflammation in a HFK model. Moreover, the nuclear expression of NF-κB p65 decreased on A20 downregulation in psoriatic tissues and keratinocytes. Interestingly, calcipotriol enhanced the binding of A20 to ring finger protein 114 (RNF114) and A20-binding inhibitor of NF-κB-1 (ABIN-1) in HFKs, two negative regulators of the NF-κB pathway.

Conclusions:
Calcipotriol exhibits its antipsoriatic function through suppressing A20 expression and stabilizing negative regulators of the NF-κB pathway.

The Blue Lagoon Geothermal Spa in Iceland is to offer free treatment to it's countries psoriasis patients.

Quote:

---

Iceland’s famous Blue Lagoon has revealed plans to save the Icelandic State millions in medical bills by providing free treatment for Icelandic sufferers of psoriasis.

The Blue Lagoon has provided treatment to sufferers of psoriasis since 1994. The treatment offered is certified by Icelandic health authorities as an official treatment option.

Until now, the cost of the treatment has been covered by the Icelandic social security for patients insured in Iceland. The Blue Lagoon has now decided to provide such treatment for free, saving the State some ISK 25 million (approx. €175,000) a year.

Patients need a prescription from their doctor to qualify for the free treatment, and some 3,000 sessions are expected annually.

This case has often been mentioned in discussions about Fumaderm (DMF) on Psoriasis Club and can sometimes end up in heated conversations which have taken some threads off topic. I personally don't have an opinion about it, but as it is back in the news again I thought I would post it here for future reference. And should it get brought up again in other threads we can move posts here.

Quote:

---

Balak and Hajdarbegovic (Aug. 6 issue) discuss an old case of Kaposi’s sarcoma2 in a patient with psoriasis who was treated with Fumaderm, a drug containing different fumaric acid esters (FAE). The authors claim that the patient had normal total lymphocyte counts before the diagnosis of Kaposi’s sarcoma, whereas the original publication shows counts of 500 to 800 per cubic millimeter for more than 18 months.

In the same issue of the Journal, van Kester et al. report a case of suspected generalized varicella–zoster virus (VZV) infection in a 23-year-old patient with psoriasis who was treated with a compounded Dutch FAE preparation for 2 months, without the development of lymphocytopenia. The authors conclude that FAE treatment may reactivate VZV infection in the absence of lymphocytopenia. However, from the clinical picture and in the absence of IgG antibodies to VZV, other interpretations need to be considered, including adult chickenpox and generalized zoster related to preexisting immune deficiencies or irrespective of immunosuppression.

Both letters reference a report previously published in the Journal of a case of progressive multifocal leukoencephalopathy (PML) in a patient with psoriasis who was treated with a compounded Dutch FAE preparation for approximately 2 years, which was reported to have occurred without severe lymphocytopenia. Such a conclusion is questionable, because lymphocytes were not monitored for 19 months before the diagnosis of PML, and the extent of lymphocytopenia during that period is unknown.

We conclude that PML and other opportunistic infections have not been observed during FAE therapy without lymphocytopenia and in the presence of appropriate monitoring and drug-discontinuation rules.

---

Drs. Balak and Hajdarbegovic reply: Reich et al. emphasize that the case of dimethyl fumarate (DMF)–related Kaposi’s sarcoma was linked to a moderate lymphocytopenia and that current drug-monitoring rules remain applicable. We conclude that the occurrence of immunosuppressive adverse events during DMF treatment is not restricted to lymphocytopenia in which the lymphocyte count is less than 500 per cubic millimeter. Illustratively, another case of treatment-related PML was reported in a patient with psoriasis who was treated with DMF and had lymphocyte counts of 500 to 1000 per cubic millimeter. In response, psoriasis guidelines have increased the threshold for dose adjustment or discontinuation of DMF in the event of a count of less than 700 lymphocytes per cubic millimeter. These drug-discontinuation rules remain to be validated. More important, absolute lymphocyte counts seem to be insensitive indicators of an increased risk of infections.1 DMF-associated moderate lymphocytopenia with selective reductions in lymphocyte subpopulations could confer a predisposition to PML, as is the case with idiopathic CD4+ lymphocytopenia.

In view of the increasing use of DMF, there is a need for more awareness and appropriate monitoring strategies to minimize risks of immunosuppression. Meanwhile, PML should be considered in patients receiving DMF who present with progressive neurologic symptoms, irrespective of the severity of lymphocytopenia.

---

Dr. van Kester and colleagues reply: We agree with Reich et al. that other interpretations of the clinical findings in our patient are possible, but these interpretations are not very likely. Varicella infection develops in 95% of the Dutch population during childhood, and our patient had reported having a previous varicella infection when he was a child, which makes the possibility of a primary varicella infection unlikely. Except for his psoriasis, our patient was healthy, and he had no history of repeated infections. We did not see an indication to exclude preexisting immunodeficiencies or human immunodeficiency virus infection, but we cannot completely rule out this unlikely explanation for the clinical findings in our patient. Therefore, we conclude that reactivation of VZV infection by FAE treatment is the most likely interpretation of the clinical findings in our patient.

---

Dr. Murk and colleagues reply: Reich et al. question our conclusion that DMF may induce PML without severe lymphocytopenia, because screening of lymphocytes in our patient contains a 19-month gap. However, none of three lymphocyte counts in the 6 months before symptom onset was below 792 cells per cubic millimeter. Moreover, three cases of FAE-associated PML without severe lymphocytopenia were published recently, corroborating our conclusion.

FAEs affect lymphocyte function, the number of lymphocytes, and the ratio of CD4 cells to CD8 cells.4 In our patient, the lymphocyte count was just below normal, with 880 cells per cubic millimeter; CD4 cells were reduced to 270 cells per cubic millimeter, and CD8 cells were reduced to 40 cells per cubic millimeter. Accordingly, a recent study showed CD4 and CD8 lymphocytopenia with a total lymphocyte count above 500 cells per cubic millimeter with DMF treatment, which is relevant because CD8 lymphocytopenia might confer a predisposition to JC-virus replication. These new insights should be taken into account when lymphocyte counts are monitored in patients receiving DMF.  

Hi
I'm new to this forum. Going through a difficult patch with my treatment at the moment. Had the condition since being a kid (now a bit older at 56). I was on acetretin for about 15 years which worked fine, only had a few patches on my legs which was easily controlled with Dovabet.
I started to get some pain and restriction in my neck which on x-Ray showed to be caused by bone spikes in my vertebrae. I was taken off acetretin immediately and started on Fumaderm. My dermatologist wanted a very slow build up of the dose and after 4 months I am only up to 1 tablet (blue) per day. Side effects aren't too bad but the psoriasis has flared up massively. I am now covered in patches and areas covered in smaller spots. Worst thing is that the palms of my hands are covered, very scaly, cracked and very sore. I've never had it on my hands before.
I would welcome any advice from members on Fumaderm. When are any positive effects likely to kick in? Any advice for soothing the hands?
Cheers
Mark

This study set out to see if infections and antibiotic use are independently associated with psoriasis in children.

Quote:

---

Importance:  
Antibiotics disrupt human microbiota and have been associated with several pediatric autoimmune diseases. Psoriasis activity has been linked to group A streptococcal and viral infections.

Objective:  
To determine whether antibiotic exposure and infections are independently associated with incident psoriasis in children.

Design, Setting, and Participants:  
This nested case-control study used data from the Health Improvement Network database, a population-representative electronic health records database from the United Kingdom, from June 27, 1994, through January 15, 2013. Data were analyzed from September 17, 2014, through August 12, 2015. Children aged 1 to 15 years with newly diagnosed psoriasis (n = 845) were compared with age- and sex-matched controls (n = 8450) randomly chosen at the time of psoriasis diagnosis from general practices with at least one case, excluding children with immunodeficiency, inflammatory bowel disease, and juvenile arthritis.

Exposures:  
Systemic antibacterial prescriptions and infections of the skin and other sites within 2 years before psoriasis diagnosis.

Main Outcomes and Measures:  
Incident psoriasis as determined by validated diagnostic codes. The association of antibiotic exposure and infections with incident psoriasis was determined by conditional logistic regression, adjusting for confounders.
Results  After adjusting for matching, country, socioeconomic deprivation, outpatient visits, and infections within the past 2 years, antibiotic exposure in the last 2 years was weakly associated with incident psoriasis (adjusted odds ratio [aOR], 1.2; 95% CI, 1.0-1.5). The associations for infections of skin (aOR, 1.5; 95% CI, 1.2-1.7) and other sites (aOR, 1.3; 95% CI, 1.1-1.6) were similar. Untreated nonskin infections (aOR, 1.5; 95% CI, 1.3-1.8) but not antibiotic-treated nonskin infections (aOR, 1.1; 95% CI, 0.9-1.4) were associated with psoriasis. Results were similar when using a lifetime exposure window. Different classes of antibiotics and age of first antibiotic exposure were also not associated with psoriasis. The findings did not substantively change when excluding periods of varying length before diagnosis.

Conclusions and Relevance:  
Infections are associated with the development of pediatric psoriasis, but antibiotics do not appear to contribute substantially to that risk.

Hi all

Even dovobet is only every so often.
I have tried every cream prescribed over the years.

I have decided to do my own research/trial

Currently i am using Sorion creme

Jay